


# Anti-inflammatory Therapeutic Market Growth, Statistics, Industry Size, Development, Trend, End User Analysis till 2028

*Anti-Inflammatory Therapeutics Market, by Drug Class and Indication Type : Global Opportunity Analysis and Industry Forecast, 2021-2028*

PORTLAND, OREGON, UNITED STATES, July 13, 2022 /EINPresswire.com/ -- [Anti-inflammatory therapeutics market](#) size was \$98,026 million in 2020 and is projected to reach \$125,552 million by 2028, registering a CAGR of 4.0% from 2021 to 2028. Anti-inflammatory therapeutics help in easing acute and chronic pain, including migraines & headaches, rheumatic arthritis, sprains, or even menstrual pain. These therapeutics provide faster relief as compared to other drugs. Moreover, they are capable of lowering the levels of prostaglandins and the chemicals responsible for inflammation as well as reducing pain and swelling.



□□□□ □□ □□□ □□□□□□□□ :

Amgen Inc  
AstraZeneca PLC.  
Eli Lilly and Company  
F. Hoffmann-La Roche AG  
GlaxoSmithKline plc  
Johnson & Johnson  
Merck & Co., Inc.  
Novartis AG  
PFIZER INC.

□□□□□□□□ □□□□□□ □□□□□□ <https://www.alliedmarketresearch.com/request-sample/286>

□□□ □□□□□□□□□ □□ □□□ □□□□□□

- North America occupied 36.64% share of the global anti-inflammatory therapeutic market in 2020.
- By indication, the arthritis segment is anticipated to grow with the highest CAGR throughout the forecast period.
- By indication, the arthritis segment was the highest contributor to the anti-inflammatory therapeutics market, with \$39,481.09 million in 2020, and is estimated to reach \$52,952.43 million by 2028, at a CAGR of 4.6% during the forecast period.
- Depending on drug class, the anti-inflammatory biologics segment accounted for \$58,618.54 million in 2020, and is estimated to reach \$77,093.85 million by 2028, registering a CAGR of 4.3%.
- Asia-Pacific is estimated to grow at the highest CAGR of 5.2% during the forecast period.

#### COVID-19 Impact:

The impact of COVID-19 pandemic is expected to remain positive for the anti-inflammatory therapeutic market, owing to the inflammation caused by SARS-COV 2. SARS-CoV-2 is a beta coronavirus causing severe anti-inflammatory pneumonia, as COVID-19 can cause severe inflammation to patients diagnosed with it. According to reports, cytokine storm is strongly responsible for death in such patients. Some of the consequences of severe inflammation and cytokine storms include acute respiratory distress syndrome, acute lung injury, and multiple organ dysfunction syndromes, which lead to increase in the research and the development of anti-inflammatory drugs for the treatment of inflammation caused by COVID-19. For example, many clinical trials are currently underway to alleviate this destructive inflammation. One of them is NLRP3 inflammasome, which targets multiple mechanisms associated with COVID-19 excessive inflammation. Thus, such factors have positively impacted the market growth during the global health crisis.

For more information, visit <https://www.alliedmarketresearch.com/purchase-enquiry/286>

The global anti-inflammatory therapeutics market is segmented into indication, drug class, and region. On the basis of indication, the market is categorized into arthritis, respiratory diseases, multiple sclerosis, psoriasis, anti-inflammatory bowel disease (IBD), and other anti-inflammatory diseases. Arthritis is expected to register the highest CAGR during the forecast period, owing to increase in geriatric population, as it is found to be more prevalent in the geriatric population and cause inflammation in joints.

Depending on drug class, it is fragmented into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologics. The nonsteroidal anti-inflammatory drugs (NSAIDs) is expected to register the highest CAGR during the forecast period, owing to increase in patient population suffering from chronic disease and unavailability of effective treatments. Moreover, increase in affordability coupled with high healthcare spending and rise in awareness of biologics, especially, in emerging markets are expected to represent a huge market potential for biologics. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for the largest market share in 2020, and is anticipated to maintain its dominance from 2020 to 2028, due to high expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to register the highest CAGR during the forecast period, as governments of Asian countries are investing in the development of healthcare infrastructure.

□□ □□□□ □□□□□□ □□□□□□ □□ □□□□□□ □□□□□□-

North America Anti-inflammatory Therapeutic Market  
Japan Anti-inflammatory Therapeutic Market  
South Korea Anti-inflammatory Therapeutic Market  
Singapore Anti-inflammatory Therapeutic Market  
Australia Anti-inflammatory Therapeutic Market  
Europe Anti-inflammatory Therapeutic Market

□□□□□ □□□□□□□□ □□□□□□□:

[Pediatric Ultrasound Market](#)

[3D Printing Healthcare Market](#)

□□□□□ □□□□□□ □□□□□□ □□□□□□□□:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa  
Allied Analytics LLP  
800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/581059246>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.